THQM Stock Overview
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria.
Tchaikapharma High Quality Medicines AD Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||лв15.60|
|52 Week High||лв15.60|
|52 Week Low||лв13.20|
|1 Month Change||1.30%|
|3 Month Change||1.96%|
|1 Year Change||9.09%|
|3 Year Change||63.64%|
|5 Year Change||167.43%|
|Change since IPO||523.86%|
Recent News & Updates
|THQM||BG Pharmaceuticals||BG Market|
Return vs Industry: THQM exceeded the BG Pharmaceuticals industry which returned -1% over the past year.
Return vs Market: THQM matched the BG Market which returned 8.8% over the past year.
|THQM Average Weekly Movement||1.3%|
|Pharmaceuticals Industry Average Movement||5.7%|
|Market Average Movement||5.2%|
|10% most volatile stocks in BG Market||8.9%|
|10% least volatile stocks in BG Market||2.5%|
Stable Share Price: THQM is less volatile than 75% of BG stocks over the past 3 months, typically moving +/- 1% a week.
Volatility Over Time: THQM's weekly volatility (1%) has been stable over the past year.
About the Company
Tchaikapharma High Quality Medicines AD engages in the development and manufacture of generic and in-licensed medicines in Bulgaria. The company offers alimentary tract and metabolism, anaesthetic, antibiotic, anti-infective, cardiovascular and musculoskeletal system, nervous system, oncology, and respiratory system medicines; and solutions for injections. It also provides nutritional supplements.
Tchaikapharma High Quality Medicines AD Fundamentals Summary
|THQM fundamental statistics|
Is THQM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|THQM income statement (TTM)|
|Cost of Revenue||лв31.69m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.018|
|Net Profit Margin||3.58%|
How did THQM perform over the long term?See historical performance and comparison
Is THQM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for THQM?
Other financial metrics that can be useful for relative valuation.
|What is THQM's n/a Ratio?|
Price to Sales Ratio vs Peers
How does THQM's PS Ratio compare to its peers?
|THQM PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
SFA Sopharma AD
600488 Tianjin Tianyao Pharmaceuticals
002907 Chongqing Pharscin Pharmaceutical
COLL Collegium Pharmaceutical
THQM Tchaikapharma High Quality Medicines AD
Price-To-Sales vs Peers: THQM is expensive based on its Price-To-Sales Ratio (30.7x) compared to the peer average (2.5x).
Price to Earnings Ratio vs Industry
How does THQM's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: THQM is expensive based on its Price-To-Sales Ratio (30.7x) compared to the European Pharmaceuticals industry average (4.1x)
Price to Sales Ratio vs Fair Ratio
What is THQM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||30.7x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate THQM's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of THQM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: THQM (BGN15.6) is trading above our estimate of fair value (BGN0)
Significantly Below Fair Value: THQM is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Tchaikapharma High Quality Medicines AD forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tchaikapharma High Quality Medicines AD has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Check out Tchaikapharma High Quality Medicines AD's track record over time to understand how much the company has returned to shareholders and its earnings growth rate in the past.
How has Tchaikapharma High Quality Medicines AD performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: THQM has high quality earnings.
Growing Profit Margin: THQM's current net profit margins (3.6%) are higher than last year (0.5%).
Past Earnings Growth Analysis
Earnings Trend: THQM's earnings have declined by 45.4% per year over the past 5 years.
Accelerating Growth: THQM's earnings growth over the past year (605.5%) exceeds its 5-year average (-45.4% per year).
Earnings vs Industry: THQM earnings growth over the past year (605.5%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: THQM's Return on Equity (1.5%) is considered low.
Discover strong past performing companies
How is Tchaikapharma High Quality Medicines AD's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: THQM's short term assets (BGN74.1M) exceed its short term liabilities (BGN15.6M).
Long Term Liabilities: THQM's short term assets (BGN74.1M) exceed its long term liabilities (BGN2.7M).
Debt to Equity History and Analysis
Debt Level: THQM's net debt to equity ratio (9.6%) is considered satisfactory.
Reducing Debt: THQM's debt to equity ratio has reduced from 12.8% to 9.6% over the past 5 years.
Debt Coverage: THQM's debt is well covered by operating cash flow (21.5%).
Interest Coverage: THQM earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Tchaikapharma High Quality Medicines AD current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THQM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THQM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THQM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THQM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: THQM is not paying a notable dividend for the BG market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as THQM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Tchaikapharma High Quality Medicines AD has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tchaikapharma High Quality Medicines AD's employee growth, exchange listings and data sources
- Name: Tchaikapharma High Quality Medicines AD
- Ticker: THQM
- Exchange: BUL
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: лв1.318b
- Shares outstanding: 84.50m
- Website: https://www.tchaikapharma.com
Number of Employees
- Tchaikapharma High Quality Medicines AD
- 1 G. M. Dimitrov Boulevard
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.